CA9 and nonpapillary renal cell carcinoma: Because of the high and specific expression levels of carbonic anhydrase IX (CAIX) in 95% of ccRCC, radiolabeled anti-CAIX chimeric monoclonal antibody girentuximab can be used for the detection of ccRCC [4, 5].